CUE-101

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameCUE-101
Drug Alias NameCUE-101LR-19127
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionImmunostimulantsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oropharyngeal NeoplasmsHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCue Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineYale UniversityLg Chemical Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oropharyngeal NeoplasmsHead and Neck Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A